BART Spólka z ograniczona odpowiedzialnoscia – Trademark Portfolio
Entity Type: 99
BART Spólka z ograniczona odpowiedzialnoscia holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include LIPOSOVIT.
Norwida 4
PL-05-250 Slupno
Showing of trademarks Trademarks
Trademark Classifications
BART Spólka z ograniczona odpowiedzialnoscia's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does BART Spólka z ograniczona odpowiedzialnoscia have?
BART Spólka z ograniczona odpowiedzialnoscia has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does BART Spólka z ograniczona odpowiedzialnoscia file in?
BART Spólka z ograniczona odpowiedzialnoscia files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are BART Spólka z ograniczona odpowiedzialnoscia's most well-known trademarks?
BART Spólka z ograniczona odpowiedzialnoscia's registered trademark portfolio includes well-known marks such as LIPOSOVIT. These are among 1 currently registered trademark in the portfolio.
What is BART Spólka z ograniczona odpowiedzialnoscia's trademark registration success rate?
BART Spólka z ograniczona odpowiedzialnoscia has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.